PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer

NCT01973660 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

151

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Lapatinib
DRUG: Trastuzumab
DRUG: Endocrine Therapy
DRUG: Paclitaxel

Sponsor

SOLTI Breast Cancer Research Group

Collaborators

[object Object]